Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes
NCT01475734
Completed
This is a stepped glucose clamp study designed to investigate the effect of treatment with albiglutide on counter-regulatory hormone responses and recovery from hypoglycemia in subjects with Type 2 diabetes mellitus. A single dose of albiglutide or placebo will be given prior to a stepped hyper- and hypoglycemic clamp. The goal of this study is to demonstrate that albiglutide increases insulin secretion and decreases glucagon levels in a glucose-dependent manner.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
11/20/2016
Locations: GSK Investigational Site, Chula Vista, California
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Safety and Efficacy Study of Albiglutide in Type 2 Diabetes
NCT00849017
Completed
The purpose of this study is to determine whether albiglutide is effective in the treament of patients with type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2016
Locations: GSK Investigational Site, Alabaster, Alabama +261 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Safety and Efficacy of Albiglutide in Type 2 Diabetes
NCT00849056
Completed
The purpose of this study is to determine the safety, tolerability and efficacy of albiglutide in the treatment of type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2016
Locations: GSK Investigational Site, Alabaster, Alabama +330 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes
NCT00838903
Completed
The purpose of this study is to determine if albiglutide is safe and effective in the treatment of type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2016
Locations: GSK Investigational Site, Birmingham, Alabama +385 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Pharmacokinetics/Pharmacodynamics of Albiglutide
NCT01357889
Completed
The first part of the study includes a single dose treatment period to evaluate the pharmacokinetic bioequivalence of a subcutaneous injection of albiglutide from process 2 drug substance compared with process 3 drug substance. The second part of the treatment period will evaluate additional pharmacokinetic and pharmacodynamic parameters and safety and tolerability of repeat doses of albiglutide given weekly for 12 weeks from process 2 drug substance compared with process 3 drug substance. Subje... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/18/2016
Locations: GSK Investigational Site, Dothan, Alabama +29 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes
NCT00838916
Completed
A study to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2016
Locations: GSK Investigational Site, Alabaster, Alabama +337 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes
NCT00839527
Completed
The purpose of this study is to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2016
Locations: GSK Investigational Site, Alabaster, Alabama +357 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects
NCT02660736
Completed
Albiglutide (Alb) is a novel analogue of glucagon-like peptide-1 (GLP-1) has been developed and approved for the treatment of type 2 diabetes mellitus. Currently, lyophilized albiglutide and the diluent are provided in a dual chamber Cartridge (DCC) single-dose pen injector, requiring reconstitution prior to use. A liquid formulation of albiglutide will enable the use of a liquid product in a ready-to-use single dose auto-injector. To support the development of the liquid auto-injector product,... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/08/2016
Locations: GSK Investigational Site, Austin, Texas
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only
NCT00518115
Completed
This study is a placebo-controlled study in patients with Type 2 Diabetes Mellitus who are either taking no diabetes medication or who are taking metformin only. This study will investigate the safety, tolerability, and efficacy of Albiglutide (GSK716155) and will measure the levels of Albiglutide (GSK716155) in the bloodstream when it is given for 16 weeks. As a comparison, some subjects will receive exenatide instead of Albiglutide (GSK716155). The study will involve weekly visits for 17 weeks... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/03/2016
Locations: GSK Investigational Site, Anniston, Alabama +162 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Modulation of Human Myocardial Metabolism by GLP-1 Dose Response
NCT01607450
Completed
The objective of this proposal is to provide quantitative dose-response data for effects of GLP-1 on myocardial glucose uptake in healthy control subjects and obese type 2 diabetic subjects, in support of the design of later studies evaluating therapeutic applications of GLP-1 to heart disease. Aim 1: To measure the effects of GLP-1 infusion on myocardial fuel selection in lean healthy humans under fasting (fatty acid-dominant) conditions. Four groups of 10 lean healthy subjects will be studied... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
01/19/2016
Locations: Indiana Clinical Research Center, Indianapolis, Indiana
Conditions: Type 2 Diabetes Mellitus, Healthy
Register for Updates
The Effect of VTC-G15 (a Pentapeptide Cleavage Product og GLP-1) on Whole Body Glucose Metabolism in Man
NCT02518932
Unknown
To asses the modulating properties of the cleaved pentapeptide product of GLP-1 amide.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/07/2015
Locations: ICON PLC, San Antonio, Texas
Conditions: Insulin Resistance
Register for Updates
Dose-response Study of Exendin-9,39 on Glucose Metabolism
NCT01218633
Completed
Multiple studies have examined the effect of endogenous GLP-1 secretions by using a competitive antagonist of GLP-1 - Exendin-9,39 - infused at rates of 300pmol/kg/min. However, the presence of an effect does not necessarily imply that this effect is due to the blockade of the endogenous GLP-1 actions at the receptor. It is possible that the supraphysiologic concentrations of Exendin may have effects of its own. To examine the effect of Exendin on glucose metabolism the investigators propose a d... Read More
Gender:
ALL
Ages:
Between 20 years and 45 years
Trial Updated:
01/18/2013
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1
Register for Updates